{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:05:49Z","timestamp":1792447549060,"version":"4.5.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"\n Importance<\/jats:title>\n The prevalence of germline pathogenic variants in familial melanoma genes has primarily been studied in individuals with a personal or family history of cancer, an approach that may introduce ascertainment bias.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To estimate the prevalence of pathogenic variants in clinically actionable familial melanoma genes and their associated cancer risks.<\/jats:p>\n <\/jats:sec>\n \n Design, Settings, and Participants<\/jats:title>\n This was a genome-first analysis of 2 population-scale genomically ascertained cohorts of individuals registered in the UK Biobank (UKBB) and the US Geisinger MyCode (GMC) databases, each linked with institutional (GMC) or national (UKBB) cancer registry data from 1970 through 2024. Data analyses were conducted from January 2025 through January 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Germline pathogenic variant status in familial melanoma genes.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n Prevalence of pathogenic variants in 8 major familial melanoma genes:\n ACD<\/jats:italic>\n ,\n BAP1<\/jats:italic>\n ,\n CDKN2A<\/jats:italic>\n ,\n CDK4<\/jats:italic>\n ,\n MITF<\/jats:italic>\n E318K,\n POT1<\/jats:italic>\n ,\n TERF2IP<\/jats:italic>\n , and\n TERT<\/jats:italic>\n promoter; and associated cancer risks among individuals in the UK and US who had been genomically ascertained. Cancer odds ratios and time to cancer analyses were adjusted for sex, birth year, body mass index, and smoking status.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The analysis included a total of 696\u202f665 individuals who were genomically ascertained, 227 286 (mean [SD] age, 57.7 [19.6] years) from GMC and 469 379 (mean [SD] age, 70.0 [8.0] years) from UKBB. The cohorts were predominantly female (GMC, 60.6%; UKBB, 54.2%), and of European genetic ancestry (GMC, 93.6%; UKBB, 94.2%). The combined prevalence of the pathogenic variants across all genes evaluated\u2014\n ACD<\/jats:italic>\n ,\n BAP1<\/jats:italic>\n ,\n CDKN2A<\/jats:italic>\n ,\n CDK4<\/jats:italic>\n ,\n MITF<\/jats:italic>\n E318K,\n POT1<\/jats:italic>\n ,\n TERF2IP<\/jats:italic>\n , and\n TERT<\/jats:italic>\n promoter\u2014ranged from 0.5% (GMC) to 0.9% (UKBB) in both cohorts. Among individuals with multiple cutaneous melanomas or a first cutaneous melanoma diagnosed before age 40 years, pathogenic variant prevalence exceeded the 2.5% threshold commonly used to recommend germline testing for high- and moderate-penetrance cancer susceptibility genes. Case-control analyses replicated established associations for\n CDKN2A<\/jats:italic>\n (brain, cutaneous melanoma, head and neck, pancreas),\n MITF<\/jats:italic>\n E318K (cutaneous melanoma, kidney), and\n POT1<\/jats:italic>\n (cutaneous melanoma, hematologic, thyroid). Additional associations, either novel or inconsistently reported, were observed for\n BAP1<\/jats:italic>\n (prostate),\n CDKN2A<\/jats:italic>\n (biliary tract, breast, nonmelanoma skin, small intestine),\n MITF<\/jats:italic>\n E318K (cervix, nasal cavity and middle ear, nonmelanoma skin), and\n POT1<\/jats:italic>\n (myeloma). In both cohorts, individuals with\n CDKN2A<\/jats:italic>\n PVs or\n MITF<\/jats:italic>\n E318K developed cutaneous melanoma at younger ages than did noncarriers, although age-of-onset patterns for internal cancers were less consistent.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, the prevalence of pathogenic variants in familial melanoma genes and their associated cancer risks were estimated, findings that may inform and revise germline testing recommendations and cancer risk counseling. These data also suggest that the spectrum of cancer risk for several genes may be broader than previously recognized.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.1305","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:30:21Z","timestamp":1779895821000},"page":"692","source":"Crossref","is-referenced-by-count":4,"title":["Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals"],"prefix":"10.1001","volume":"162","author":[{"given":"Alisa M.","family":"Goldstein","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Haley","sequence":"additional","affiliation":[{"name":"Department of Genomic Health, Geisinger Clinic, Geisinger Health System, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Genomic Health, Geisinger Clinic, Geisinger Health System, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane T.","family":"Smelser","sequence":"additional","affiliation":[{"name":"Department of Genomic Health, Geisinger Clinic, Geisinger Health System, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Shanker","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Genomic Health, Geisinger Clinic, Geisinger Health System, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica N.","family":"Hatton","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong R.","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Tucker","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G.","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Waters","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Adams","sequence":"additional","affiliation":[{"name":"Wellcome Sanger Institute, Hinxton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Marston","family":"Linehan","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Medical Center Hillman Cancer Center Melanoma Program, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kanetsky","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Carey","sequence":"additional","affiliation":[{"name":"Department of Genomic Health, Geisinger Clinic, Geisinger Health System, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Stewart","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Sargen","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi260016r1","first-page":"10","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"doi260016r2","doi-asserted-by":"publisher","first-page":"677.e1","DOI":"10.1016\/j.jaad.2009.03.016","article-title":"Selection criteria for genetic assessment of patients with familial melanoma.","volume":"61","author":"Leachman","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"doi260016r3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076962","article-title":"25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis.","volume":"384","author":"Shelton","year":"2024","journal-title":"BMJ"},{"issue":"6","key":"doi260016r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2022.100152","article-title":"New insights into melanoma tumor syndromes.","volume":"2","author":"Rashid","year":"2022","journal-title":"JID Innov"},{"key":"doi260016r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2024.100837","article-title":"Unveiling the genetic landscape of hereditary melanoma: from susceptibility to surveillance.","volume":"40","author":"Zheng","year":"2024","journal-title":"Cancer Treat Res Commun"},{"issue":"15","key":"doi260016r6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1056\/NEJM199510123331504","article-title":"Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.","volume":"333","author":"Goldstein","year":"1995","journal-title":"N Engl J Med"},{"issue":"4","key":"doi260016r7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1136\/jmedgenet-2019-106562","article-title":"Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants.","volume":"58","author":"Overbeek","year":"2021","journal-title":"J Med Genet"},{"issue":"6","key":"doi260016r8","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac074","article-title":"Impact of transcript (p16\/p14ARF) alteration on cancer risk in cdkn2a germline pathogenic variant carriers.","volume":"6","author":"Sargen","year":"2022","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"21","key":"doi260016r9","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-08-0403","article-title":"Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.","volume":"14","author":"de Snoo","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"doi260016r10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/ejhg.2014.187","article-title":"Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant.","volume":"23","author":"Potjer","year":"2015","journal-title":"Eur J Hum Genet"},{"issue":"8","key":"doi260016r11","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/jmedgenet-2014-102320","article-title":"High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.","volume":"51","author":"Helgadottir","year":"2014","journal-title":"J Med Genet"},{"issue":"20","key":"doi260016r12","doi-asserted-by":"publisher","first-page":"9818","DOI":"10.1158\/0008-5472.CAN-06-0494","article-title":"High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.","volume":"66","author":"Goldstein","year":"2006","journal-title":"Cancer Res"},{"issue":"10","key":"doi260016r13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamadermatol.2023.2621","article-title":"Estimated prevalence, tumor spectrum, and neurofibromatosis type 1-like phenotype of CDKN2A-related melanoma-astrocytoma syndrome.","volume":"159","author":"Sargen","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi260016r14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jaad.2014.06.036","article-title":"Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.","volume":"71","author":"Potrony","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi260016r15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma.","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"12","key":"doi260016r16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide.","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"doi260016r17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas.","volume":"92","author":"Popova","year":"2013","journal-title":"Am J Hum Genet"},{"issue":"9","key":"doi260016r18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Cancer Res"},{"issue":"12","key":"doi260016r19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"issue":"7375","key":"doi260016r20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature10539","article-title":"A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma.","volume":"480","author":"Bertolotto","year":"2011","journal-title":"Nature"},{"issue":"1","key":"doi260016r21","first-page":"384","article-title":"Germline mutations in shelterin complex genes are associated with familial glioma.","volume":"107","author":"Bainbridge","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"doi260016r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100937","article-title":"Characterization of POT1 tumor predisposition syndrome: tumor prevalence in a clinically diverse hereditary cancer cohort.","volume":"25","author":"Herrera-Mullar","year":"2023","journal-title":"Genet Med"},{"key":"doi260016r23","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00946","article-title":"Germline POT1 variants in a pan-cancer cohort.","volume":"9","author":"Brock","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"doi260016r24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41375-021-01335-w","article-title":"Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.","volume":"36","author":"Lim","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"doi260016r25","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1182\/blood-2016-01-695692","article-title":"Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.","volume":"128","author":"Speedy","year":"2016","journal-title":"Blood"},{"issue":"5","key":"doi260016r26","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.ajhg.2018.03.012","article-title":"Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes.","volume":"102","author":"Staples","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"D1","key":"doi260016r28","doi-asserted-by":"publisher","first-page":"D835","DOI":"10.1093\/nar\/gkz972","article-title":"ClinVar: improvements to accessing data.","volume":"48","author":"Landrum","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"doi260016r29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jaad.2022.05.022","article-title":"Variation in second cancer risk by melanoma subtype among survivors.","volume":"88","author":"Luu","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"35","key":"doi260016r30","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1200\/JCO.22.00120","article-title":"Development and validation of the PREMMplus model for multigene hereditary cancer risk assessment.","volume":"40","author":"Yurgelun","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"doi260016r31","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.ejca.2010.01.027","article-title":"MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.","volume":"46","author":"Fargnoli","year":"2010","journal-title":"Eur J Cancer"},{"issue":"20","key":"doi260016r32","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1093\/jnci\/djq363","article-title":"Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.","volume":"102","author":"Demenais","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"7375","key":"doi260016r33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature10630","article-title":"A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.","volume":"480","author":"Yokoyama","year":"2011","journal-title":"Nature"},{"issue":"5","key":"doi260016r34","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/ng.2947","article-title":"POT1 loss-of-function variants predispose to familial melanoma.","volume":"46","author":"Robles-Espinoza","year":"2014","journal-title":"Nat Genet"},{"issue":"5","key":"doi260016r35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/ng.2941","article-title":"Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.","volume":"46","author":"Shi","year":"2014","journal-title":"Nat Genet"},{"issue":"10","key":"doi260016r36","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors.","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat Genet"},{"issue":"4","key":"doi260016r37","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/jha2.557","article-title":"A germline exome analysis reveals harmful POT1 variants in multiple myeloma patients and families.","volume":"3","author":"Hakkarainen","year":"2022","journal-title":"EJHaem"},{"issue":"4","key":"doi260016r38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<441::AID-IJC2>3.0.CO;2-R","article-title":"Characterization of ligurian melanoma families and risk of occurrence of other neoplasia.","volume":"83","author":"Ghiorzo","year":"1999","journal-title":"Int J Cancer"},{"issue":"11","key":"doi260016r39","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41431-023-01448-z","article-title":"Clinical practice guidelines for the diagnosis and surveillance of BAP1 tumour predisposition syndrome.","volume":"31","author":"Lalloo","year":"2023","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"doi260016r40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1878-0261.12844","article-title":"BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN.","volume":"15","author":"Deng","year":"2021","journal-title":"Mol Oncol"},{"issue":"7726","key":"doi260016r41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data.","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"9","key":"doi260016r42","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population.","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"key":"doi260016r27","unstructured":"Priv\u00e9? F. Code to reproduce ancestry groups. Accessed April 27, 2026. https:\/\/github.com\/privefl\/UKBB-PGS"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2849565\/jamadermatology_goldstein_2026_oi_260016_1783528899.30735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:54Z","timestamp":1784127654000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2849565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.1305","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}